Literature DB >> 30708238

Current status and management of canine leishmaniasis in Latin America.

Mary Marcondes1, Michael J Day2.   

Abstract

Latin America encompasses diverse geographical, cultural and socio-economic conditions, which are reflected in the challenges for infectious disease control in the region. One of the most significant regional infectious diseases for humans and domestic dogs is leishmaniasis, occurring as visceral leishmaniasis (VL) caused by Leishmania infantum (syn. L. chagasi) transmitted by sand flies (Lutzomyia longipalpis) and with a canine reservoir, and the more common cutaneous leishmaniasis (CL) involving multiple Leishmania spp. (particularly L. braziliensis), sand fly vectors and reservoir hosts. VL is spreading within Latin America for reasons related to mass migration of human and canine populations, with incursion into novel environments (e.g. related to deforestation) coupled with a background of poverty and poor public health infrastructure. The challenges for control of VL also include: (1) the accurate identification of infected dogs (particularly subclinically infected dogs) with the current reliance on serological rather than molecular diagnostic methods, (2) controversy surrounding the ethics and efficacy of culling of seropositive dogs, (3) the limited efficacy of currently available canine vaccines and their potential to interfere with interpretation of serological testing, (4) the expense associated with distribution of insecticidal dog collars, which may prove to be the most valuable control method, and (5) the cost and therefore accessibility of licensed medical treatment for canine leishmaniasis by the general population. Resolution of these isssues will necessitate a 'One Health' approach to co-ordination of resources between human and veterinary healthcare.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cutaneous leishmaniasis; Dog; Epidemiology; Infectious disease control; Visceral leishmaniasis

Mesh:

Year:  2019        PMID: 30708238     DOI: 10.1016/j.rvsc.2019.01.022

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  17 in total

1.  Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis.

Authors:  Beatriz Coutinho De Oliveira; Malcolm S Duthie; Valéria Rêgo Alves Pereira
Journal:  Hum Vaccin Immunother       Date:  2019-11-11       Impact factor: 3.452

2.  First Report of an Urban Case of Canine Visceral Leishmaniasis in the Municipality of Cali, Colombia.

Authors:  Natalia Arbeláez; Jaime Moreno; Javier Murillo; Andrés Montoya; Sara M Robledo; Andrés Vélez; Iván D Vélez
Journal:  Am J Trop Med Hyg       Date:  2020-02       Impact factor: 2.345

3.  Recombinant Cysteine Proteinase B from Leishmania braziliensis and Its Domains: Promising Antigens for Serodiagnosis of Cutaneous and Visceral Leishmaniasis in Dogs.

Authors:  A E Bivona; L Czentner; A Sanchez Alberti; N Cerny; A C Cardoso Landaburu; C Nevot; O Estévez; J D Marco; M A Basombrio; E L Malchiodi; S I Cazorla
Journal:  J Clin Microbiol       Date:  2019-10-23       Impact factor: 5.948

Review 4.  Diversity and evolution of the animal virome.

Authors:  Erin Harvey; Edward C Holmes
Journal:  Nat Rev Microbiol       Date:  2022-01-04       Impact factor: 60.633

5.  A new immunochemotherapy schedule for visceral leishmaniasis in a hamster model.

Authors:  Fabiana Rodrigues de Santana; Danielle Aparecida Marino da Silva; Simone Katz; Cristina Mary Orikaza; Katia Cristina Oliveira; Clara Lúcia Barbiéri
Journal:  Parasitol Res       Date:  2022-08-23       Impact factor: 2.383

6.  Monitoring of serum and urinary biomarkers during treatment of canine visceral leishmaniasis.

Authors:  Alvaro Felipe de Lima Ruy Dias; Eveline da Cruz Boa Sorte Ayres; Fernanda Harumi Maruyama; Bruna Ribeiro Gomes Monteiro; Maria Sabrina de Freitas; Arleana do Bom Parto Ferreira de Almeida; Adriane Jorge Mendonça; Valéria Régia Franco Sousa
Journal:  Vet World       Date:  2020-08-18

7.  Gene design, optimization of protein expression and preliminary evaluation of a new chimeric protein for the serological diagnosis of both human and canine visceral leishmaniasis.

Authors:  Wagner J T Santos; Diego H C Tavares; Artur L Castro Neto; Marília B Nascimento; Rafael Dhalia; Alessandra L Albuquerque; Carlos H N Costa; Franklin B Magalhães; Antônio M Rezende; Osvaldo P de Melo Neto
Journal:  PLoS Negl Trop Dis       Date:  2020-07-27

8.  Mathematical Modelling Using Predictive Biomarkers for the Outcome of Canine Leishmaniasis upon Chemotherapy.

Authors:  Rafaela de Sousa Gonçalves; Flaviane Alves de Pinho; Ricardo Jorge Dinis-Oliveira; Rui Azevedo; Joana Gaifem; Daniela Farias Larangeira; Eduardo Milton Ramos-Sanchez; Hiro Goto; Ricardo Silvestre; Stella Maria Barrouin-Melo
Journal:  Microorganisms       Date:  2020-05-15

Review 9.  An Overview of Immunotherapeutic Approaches Against Canine Visceral Leishmaniasis: What Has Been Tested on Dogs and a New Perspective on Improving Treatment Efficacy.

Authors:  Ana Alice Maia Gonçalves; Jaqueline Costa Leite; Lucilene Aparecida Resende; Reysla Maria da Silveira Mariano; Patricia Silveira; Otoni Alves de Oliveira Melo-Júnior; Helen Silva Ribeiro; Diana Souza de Oliveira; Diogo Fonseca Soares; Thaiza Aline Pereira Santos; Alexandre Ferreira Marques; Alexsandro Sobreira Galdino; Olindo Assis Martins-Filho; Walderez Ornelas Dutra; Denise da Silveira-Lemos; Rodolfo Cordeiro Giunchetti
Journal:  Front Cell Infect Microbiol       Date:  2019-12-18       Impact factor: 5.293

10.  Recommendations on vaccination for Latin American small animal practitioners: a report of the WSAVA Vaccination Guidelines Group.

Authors:  M J Day; C Crawford; M Marcondes; R A Squires
Journal:  J Small Anim Pract       Date:  2020-03-30       Impact factor: 1.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.